Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study

[1]  K. Boye,et al.  Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database , 2016, Patient preference and adherence.

[2]  K. Boye,et al.  Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan , 2016, Patient preference and adherence.

[3]  S. Grandy,et al.  Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany , 2016, Diabetes, metabolic syndrome and obesity : targets and therapy.

[4]  S. Simpson,et al.  Medication Adherence Affects Risk of New Diabetes Complications , 2016, The Annals of pharmacotherapy.

[5]  L. Jaacks,et al.  Type 2 diabetes: A 21st century epidemic. , 2016, Best practice & research. Clinical endocrinology & metabolism.

[6]  D. Giugliano,et al.  Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes—2016. Diabetes Care 2016;39(Suppl. 1):S52–S59 , 2016, Diabetes Care.

[7]  James Chamberlain,et al.  Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes , 2016, Annals of Internal Medicine.

[8]  M. Pencina,et al.  Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. , 2016, American heart journal.

[9]  A. Hauber,et al.  A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes , 2016, Current medical research and opinion.

[10]  S. Madsbad,et al.  Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review , 2016, Expert review of clinical pharmacology.

[11]  S. Madsbad.  Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists , 2015, Diabetes, obesity & metabolism.

[12]  K. Boye,et al.  Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK , 2015, Patient preference and adherence.

[13]  E. Buysman,et al.  Impact of Medication Adherence and Persistence on Clinical and Economic Outcomes in Patients with Type 2 Diabetes Treated with Liraglutide: A Retrospective Cohort Study , 2015, Advances in Therapy.

[14]  F. Mittermayer,et al.  Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development , 2015, Current diabetes reviews.

[15]  Jennifer M. Trujillo,et al.  GLP-1 receptor agonists: a review of head-to-head clinical studies , 2015, Therapeutic advances in endocrinology and metabolism.

[16]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2014, Diabetes Care.

[17]  Hiep Nguyen,et al.  Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States , 2014, Advances in Therapy.

[18]  Jennifer M. Trujillo,et al.  GLP‐1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents , 2014, Pharmacotherapy.

[19]  H. Hammes,et al.  ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD , 2013 .

[20]  Jerry D Meece,et al.  Improving Medication Adherence Among Patients With Type 2 Diabetes , 2014, Journal of pharmacy practice.

[21]  S. Doggrell,et al.  The association between the measurement of adherence to anti-diabetes medicine and the HbA1c , 2014, International Journal of Clinical Pharmacy.

[22]  Jiang He,et al.  Prevalence and control of diabetes in Chinese adults. , 2013, JAMA.

[23]  Tatiana Dilla,et al.  Adherence to Therapies in Patients with Type 2 Diabetes , 2013, Diabetes Therapy.

[24]  Audrey J Weiss,et al.  Predictors of medication adherence in patients with type 2 diabetes mellitus , 2013, Current medical research and opinion.

[25]  De-Min Yu,et al.  Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables , 2013, BMC Public Health.

[26]  L. J. Gray,et al.  Real‐world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review , 2013, Diabetic medicine : a journal of the British Diabetic Association.

[27]  M. Lemstra,et al.  Non-adherence in type 2 diabetes: practical considerations for interpreting the literature , 2013, Patient preference and adherence.

[28]  Mandy Ryan,et al.  Discrete choice experiments in health economics: a review of the literature. , 2012, Health economics.

[29]  A. Garber.  Novel GLP-1 receptor agonists for diabetes , 2012, Expert opinion on investigational drugs.

[30]  Li Yan,et al.  Determinants for inadequate glycaemic control in Chinese patients with mild-to-moderate type 2 diabetes on oral antidiabetic drugs alone. , 2011, Chinese medical journal.

[31]  V. Fonseca.  Defining and Characterizing the Progression of Type 2 Diabetes , 2009, Diabetes Care.

[32]  Anke Richter,et al.  The impact of reducing dose frequency on health outcomes. , 2003, Clinical therapeutics.

[33]  A Ludbrook,et al.  Use of discrete choice experiments to elicit preferences , 2001, Quality in health care : QHC.

[34]  BOULIN,et al.  Classification and Diagnosis of Diabetes. , 2022, Primary care.

[35]  R. Swindle,et al.  Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation. , 2016, Clinical therapeutics.

[36]  C. Asche,et al.  A review of diabetes treatment adherence and the association with clinical and economic outcomes. , 2011, Clinical therapeutics.

[37]  J. Shaw,et al.  Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.

[38]  Approaches to Glycemic Treatment , 2022 .